Southeast Texas Record

Sunday, February 16, 2020

Former Novo employee claims company is using non-compete clause to restrain her research on hemophilia therapies

Lawsuits

By Marian Johns | Jan 21, 2020

Medicalreseach

HOUSTON – A former Novo employee is claiming the company is using a non-compete agreement to prevent her from working on "revolutionary" hemophilia gene therapy for another pharmaceutical business. 

Julie Golla filed a complaint Jan. 8 in the Houston Division of the Southern District of Texas against Novo Nordisk Inc., seeking a declaratory judgment. 

Golla, a 25-year veteran of the pharmaceutical field, began working for Novo in November of 2018 as a senior hemophilia therapy manager for the company's Factor VIII replacement therapies. On Jan. 7, Golla announced her resignation and intention to work for BioMarin in hemophilia gene therapy. In her complaint, she alleges Novo is attempting to use a non-competition agreement to "restrain" her from working at BioMarin on a potential "revolutionary gene therapy" for hemophilia patients. 

Golla seeks monetary and all other proper relief. She is represented by Matthew Ray of Loewinsohn Flegle Deary Simon LLP in Dallas. 

Houston Division of the Southern District of Texas case No. 4:20-CV-00071

Want to get notified whenever we write about Houston Division of the Southern District of Texas ?

Sign-up Next time we write about Houston Division of the Southern District of Texas, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Houston Division of the Southern District of Texas

More News